BSX logoBSX
Boston Scientific Corp.

6,452
Loading...
Loading...
News
all
press releases
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Down 10.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Boston Scientific (BSX)
Boston Scientific (BSX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·2d ago
News Placeholder
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
Zacks·2d ago
News Placeholder
The Zacks Analyst Blog Highlights Boston Scientific, Union Pacific, Realty Income and Weyco
BSX, UNP, O, and WEYS stand out with strong sector performance, resilient cash flows, and strategic growth moves, despite headwinds from tariffs, e-commerce, and macro uncertainties.
Zacks·2d ago
News Placeholder
Top Research Reports for Boston Scientific, Union Pacific & Realty Income
Boston Scientific gains from MedSurg and cardiovascular strength, while Union Pacific and Realty Income face mixed headwinds.
Zacks·3d ago
News Placeholder
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.
Zacks·4d ago
News Placeholder
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Zacks·4d ago
News Placeholder
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
Zacks·6d ago
News Placeholder
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Zacks·9d ago
News Placeholder
Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?
PAHC rallies 82% YTD with booming vaccines, MFAs and global expansion fueling investor confidence.
Zacks·10d ago

Latest BSX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.